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Recently, hepatic peroxisome proliferator-activated receptor (PPAR)γ
has been implicated in hepatic lipid accumulation. We found that the
C3H mouse strain does not express PPARγ in the liver and, when
subject to a high-fat diet, is resistant to hepatic steatosis, compared
with C57BL/6 (B6) mice. Adenoviral PPARγ2 injection into B6 and
C3H mice caused hepatic steatosis, and microarray analysis demon-
strated that hepatic PPARγ2 expression is associated with genes
involved in fatty acid transport and the triglyceride synthesis path-
way. In particular, hepatic PPARγ2 expression signiﬁcantly increased
the expression of monoacylglycerol O-acyltransferase 1 (MGAT1).
Promoter analysis by luciferase assay and electrophoretic mobility
shift assay as well as chromatin immunoprecipitation assay revealed
that PPARγ2 directly regulates the MGAT1 promoter activity. The
MGAT1 overexpression in cultured hepatocytes enhanced triglycer-
ide synthesis without an increase of PPARγ expression. Importantly,
knockdown of MGAT1 in the liver signiﬁcantly reduced hepatic stea-
tosis in 12-wk-old high-fat–fed mice as well as ob/ob mice, accom-
panied by weight loss and improved glucose tolerance. These results
suggest that the MGAT1 pathway induced by hepatic PPARγ is crit-
ically important in the development of hepatic steatosis during diet-
induced obesity.
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Metabolic syndrome is characterized by a combination ofcentral obesity, dyslipidemia, hypertension, hepatic steatosis,
and abnormal glucose tolerance (1). Although the exact etiology of
metabolic syndrome has not yet been deﬁned, most patients have
some degree of insulin resistance, which is considered an un-
derlying mechanism in development of a combination of disorders
(2). Metabolic syndrome is closely associated with nonalcoholic
fatty liver disease, characterized by an increased hepatic lipid
content (i.e., hepatic steatosis) (3). It is widely believed that an
excessive amount of intrahepatic triglyceride (TG) results from an
imbalance between complex interactions of metabolic events.
To date, two major transcription factors, sterol regulatory ele-
ment-binding protein 1c (SREBP1c) and carbohydrate responsive
element-binding protein (ChREBP), have been implicated in fatty
liver formation (4). SREBP1c, stimulated by insulin during the
postprandial state, regulates a cluster of genes involved in glycol-
ysis and fatty acid synthesis, thereby inducing conversion of excess
dietary glucose into TG in the liver. ChREBP also regulates
a similar pathway through liver-type pyruvate kinase expression as
well as lipogenic genes (5). However, many studies have demon-
strated that these two transcription factors are essentially associ-
ated with regulating de novo fatty acid synthesis from the
carbohydrate sources of a diet (4). It is still uncertain whether these
two transcription factors are involved in high-fat–induced severe
hepatic steatosis in a living animal.
In contrast to these two transcription factors, peroxisome
proliferator-activated receptor γ (PPARγ) was recently described
as involved in hepatic steatosis. Generally, PPARγ is expressed
at a low level in human and mouse liver, ∼10–30% of that in
adipose tissue (6). However, there is emerging evidence that
hepatic PPARγ plays an important role in metabolic syndrome.
First, it was reported that liver PPARγ2 was signiﬁcantly up-
regulated in a rodent model of obesity, indicating that PPARγ
plays an important role in fatty liver formation (7, 8). In this
regard, it was not surprising that inhibition of retinoid X receptor
(RXR) and PPARγ ameliorated diet-induced obesity (DIO) and
diabetes (9). Accordingly, liver-speciﬁc disruption of PPARγ in
ob/ob mice improves fatty liver (10). This deﬁciency of hepatic
PPARγ in ob/ob mice, however, showed further aggravation of
diabetes accompanied by decreased insulin sensitivity in muscle
and fat (10). Therefore, although the relationship between he-
patic steatosis and systemic insulin resistance remains to be
further deﬁned, these results strongly suggest that the PPARγ
signaling pathway is involved in diet-induced liver steatosis, and
lipid accumulation may be prevented by down-regulation of the
PPARγ gene in the hepatocytes.
The molecular mechanism of how PPARγ induces hepatic
steatosis is not fully understood. When the hepatocytes aberrantly
express PPARγ at a high level, several adipocyte-speciﬁc genes and
lipogenesis-related genes are induced, such as adipsin, adipo-
nectin, aP2/422, and fat-speciﬁc gene 27 (FSP27) (11). Other
reports showed that adipose differentiation-related protein
(ADRP) was up-regulated in PPARγ-overexpressing hepatocytes
(12). These results suggest that hepatic PPARγ enhances lipid
accumulation in liver mainly through the up-regulation of adipo-
genic genes; however, it remains to be seen whether PPARγ
directly regulates genes involved in hepatic lipid metabolism, in-
cluding the TG synthesis pathway.
In this study, we found that C3H mice do not express PPARγ in
the liver and are resistant to hepatic steatosis when fed a high-fat
diet (HFD). Using the advantage of this animal model, we found
that monoacylglycerol O-acyltransferase 1 (MGAT1) is directly
regulated by PPARγ and plays a role in regulating the pathway
leading to incorporation of fatty acid into TG. Our data suggest
that increased PPARγ and MGAT1 activity during a HFD plays
Author contributions: Y.J.L., E.H.K., and J.-w.K. designed research; Y.J.L., E.H.K., J.E.K.,
E.K., H.L., H.C., J.H.Y., and J.-w.K. performed research; J.-K.S. contributed new reagents/
analytic tools; Y.J.L., E.H.K., H.J.K., J.-K.S., K.-S.K., and J.-w.K. analyzed data; and Y.J.L. and
J.-w.K. wrote the paper.
The authors declare no conﬂict of interest.
This article is a PNAS Direct Submission. E.D.R. is a guest editor invited by the Editorial
Board.
1To whom correspondence should be addressed. E-mail: japol13@yuhs.ac.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1203218109/-/DCSupplemental.
13656–13661 | PNAS | August 21, 2012 | vol. 109 | no. 34 www.pnas.org/cgi/doi/10.1073/pnas.1203218109
a major role in developing hepatic steatosis by regulating fatty
acid transport and the TG incorporation pathway.
Results
C3H Mice Do Not Express PPARγ in Liver and Are Resistant to Hepatic
Steatosis During a HFD. C57BL/6 (B6) mice are largely used in
metabolic disease research because they develop severe obesity and
diabetes after severalweeksof aHFD(13).ComparedwithB6mice,
we examined the metabolic proﬁle of C3H mice under a normal
chow diet (CD) or a HFD. High-fat–fed B6 mice showed signiﬁ-
cantly higher ﬁnal body weight and cumulative body weight gain
compared with CD-fed mice (Fig. 1A). Importantly, HFD-fed C3H
mice also showed signiﬁcantly higher ﬁnal body weight, indicating
that thesemice should be considered aDIO-prone strain.However,
C3Hmice showednormal glucose tolerancedespite a highdegree of
obesity (Fig. 1B). In addition, plasmaLDLcholesterol did not rise to
a signiﬁcant level in C3H compared with B6 mice when both were
fed theHFD(TableS1), suggesting thatC3Hmicemight beamouse
strain that represents less clinically harmfulhumanobesity.Whereas
the liver weight of HFD-fed B6 mice was signiﬁcantly higher than
that of CD-fed B6 mice, there was no difference in liver weight be-
tween HFD-fed and CD-fed C3H mice (Fig. S1A). Both mouse
strains had markedly increased fat pads after HFD, explaining the
similar weight gain. It should be noted that HFD-fed B6 mice had
larger epididymal fat pads compared with C3Hmice, whereas C3H
mice had larger s.c. fat pads (Fig. S1B). This result is noteworthy
because the visceral fat content rather than s.c. fat content is known
to contribute to the development of metabolic syndrome. As shown
by the increased liver weight, severe hepatic steatosis was observed
with increased liver TG level in HFD-fed B6 compared with HFD-
fed C3H mice (Fig. 1 C and D).
Strikingly, liver PPARγ (mainly PPARγ2) mRNA and protein
were markedly elevated in B6 but not in C3H mice after 12 wk of
HFD (Fig. 1E and Fig. S1 C and D). In addition, PPARγ binding
activity in EMSA experiments showed the same pattern as that of
the mRNA changes (Fig. S1E). The near absence of both
PPARγ1 and PPARγ2 expression in the liver of C3H mice even
under CD should be noted (Fig. 1E). Importantly, white adipose
tissue of C3H mice expressed PPARγ as much as that of B6 mice,
indicating that the phenomenon we observe in this study is liver-
speciﬁc (Fig. S1C). Meanwhile, previous reports indicated that
a loss-of-function mutation in the Toll-like receptor (TLR4) in
C3H/HeJ mice prevents diet-induced obesity and insulin re-
sistance (14, 15). However, we found that both the C3H/HeN
mice (carrying wild-type TLR4) and the C3H/HeJ mice (carrying
mutated TLR4) did not show the difference in hepatic steatosis in
response to 12-wk HFD (Fig. S2). Moreover, both C3H/HeN and
C3H/HeJ mice showed similar patterns of PPARγ expression in
liver (Fig. S2G), suggesting that mice lacking hepatic PPARγ
expression may be protected against the development of hepatic
steatosis and glucose intolerance under HFD conditions, in-
dependent of TLR4 function. It is not clear why C3H mice do not
express PPARγ in the liver, but the epigenetic control may partly
contribute to this phenomenon. Although methylation status in
the PPARγ1 and the PPARγ2 promoter did not show any dif-
ferences between livers of B6 and C3Hmice (Fig. S3A), increased
H3 acetylation in the promoter regions of PPARγ1 and PPARγ2
of B6 mice compared with C3H mice was observed (Fig. S3B).
Hepatic PPARγ Regulates Expression of Genes Related to Fatty Acid
Transport and TG Synthesis. To verify the functional signiﬁcance of
PPARγ in the fatty liver in vivo, we injected adenoviral PPARγ2
(Ad-PPARγ2) into B6 and C3H mice via tail veins, resulting in
overexpression of PPARγ2. Ectopic expression of hepatic
PPARγ2 was veriﬁed by real-time PCR as well as Western blot
analysis (Fig. 2 A and B). As expected, PPARγ2 overexpression
resulted in a marked induction of several PPARγ targets, in-
cluding aP2/422, CD36, and ADRP (Fig. 2 A and B). Consis-
tently, Ad-PPARγ2 mice showed higher levels of hepatic TG
than control Ad-GFP mice (Fig. 2C). Histological analysis of the
liver from Ad-GFP or Ad-PPARγ2 mice revealed the presence
of numerous fat droplets in the Ad-PPARγ2–injected B6 and
C3H mice (Fig. 2D). It should be noted that the PPARγ ex-
pression after adenovirus injection into B6 mice was 1.8-fold
higher compared with that in C3H mice (Fig. 2 A and B). The
reason for the difference in the level of overexpression attained
in each strain remains uncertain, but the degree of hepatic
steatosis in B6 and C3H mice (Fig. 2 C and D) was correlated
with the degree of PPARγ expression.
These ﬁndings were conﬁrmed in vitro, using primary hep-
atocytes from B6 and C3H mice with PPARγ2 overexpression.
When Ad-PPARγ2 was added to primary hepatocytes, aP2/422,
CD36, and FSP27 were expressed both in B6 and in C3H hep-
atocytes, which was further enhanced with a PPARγ agonist,
rosiglitazone treatment (Fig. S4 A and B). Consistent with pre-
vious ﬁndings, the TG level signiﬁcantly increased in primary
hepatocytes with Ad-PPARγ2 virus compared with Ad-GFP vi-
rus (Fig. S4C). Indeed, the TG level increased further by the
addition of palmitate, suggesting that PPARγ2 is involved in the
fatty acid incorporation pathway. As previously reported (12),
alpha mouse liver (AML)-12 hepatocytes infected by Ad-
PPARγ2 virus also demonstrated that ADRP coats lipid droplets
in PPARγ2-expressing hepatocytes at higher levels compared
with levels observed in control hepatocytes (Fig. S4D), sup-
porting a critical role of PPARγ in hepatic TG synthesis.
To analyze the proﬁle of PPARγ-regulated genes in steatotic liver,
we performed two sets of microarray experiments using RNAs from
B6 vs. C3H with CD or HFD and B6 and C3H with or without Ad-
PPARγ2 injection. Data in Table S2 and Fig. S5A indicate that he-
patic PPARγ induces genes mainly involved in cellular uptake and
TG incorporation of fatty acids. It is noteworthy that C3H liver
expressed a considerable amount of SREBP1c in response to HFD
Fig. 1. Comparison of metabolic response to high-fat diet between B6 and
C3H mice. (A) Body weight changes of B6 and C3H mice fed a CD or a HFD.
*P < 0.05, **P < 0.01 relative to diet-matched B6 and C3H mice, and ##P <
0.01 relative to corresponding CD controls. (B) Glucose tolerance test in B6
and C3H mice fed CD or HFD. *P < 0.05, **P < 0.01 for B6 vs. C3H with CD or
HFD, respectively. (C) TG content in the livers of B6 and C3H mice. **P < 0.01
relative to corresponding CD controls, and ##P < 0.01 between HFD groups.
Data in A–C represent the mean ± SD and were analyzed by two-way
ANOVA (CD and HFD: n = 8 and 9, respectively). (D) Increased lipid de-
position, as indicated by oil-Red-O lipid staining in liver sections from mice in
the CD or HFD groups at 12 wk. (E) Hepatic PPARγ2 mRNA expression
measured by real-time PCR in liver from B6 and C3H mice fed CD or HFD at
12 wk. **P < 0.01. Data represent the mean ± SD.
Lee et al. PNAS | August 21, 2012 | vol. 109 | no. 34 | 13657
CE
LL
BI
O
LO
G
Y
(Fig. S5A), and therefore there is no remarkable difference of lipo-
genic genes such asACL,ACC, and FAS between B6 andC3Hmice.
To study how PPARγ overexpression affects fatty acid transport, we
adopted real-time quantiﬁcation of fatty acid uptake, using a ﬂuo-
rescence assay (16). As shown in Fig. S5B, adenoviral overexpression
of PPARγ2 resulted in increased fatty acid transport into the hep-
atocytes isolated both from B6 and from C3H mice. Baseline fatty
acid transport was also higher in B6 mice than in C3H mice. This
phenomenon was reversed by the addition of GW9662, a synthetic
PPARγ antagonist. Therefore, it is concluded that at least one
mechanism related to PPARγ activity in hepatic steatosis is involved
in this increase of fatty acid transport. This activity likely occurs
through the induction of aP2/422 and CD36.
Hepatic PPARγ Directly Regulates the Expression of MGAT1. In-
terestingly, PPARγ2 overexpression caused a marked induction
of MGAT1 (Table S2 and Fig. S5A). This enzyme is involved in
incorporation of fatty acids into TG (17, 18), providing an al-
ternative pathway for TG synthesis that has also been demon-
strated in 1-acylglycerol-3-phosphate O-acyltransferase 2
(AGPAT2) knockout mice (18). Indeed, MGAT1 was induced
both by HFD-induced steatosis and by Ad-PPARγ2 over-
expression (Fig. 3A). Furthermore, knockdown of PPARγ using
siRNA in primary hepatocytes showed marked reduction of
MGAT1 expression (Fig. 3B). This result opens the possibility
that PPARγ activates the MGAT pathway, leading to acceler-
ated TG synthesis from excessive amounts of fatty acids, and
MGAT1 is one of the target genes regulated by PPARγ. To
access this hypothesis, we analyzed ∼2 kb of the MGAT1 pro-
moter sequence. Computer analysis of the mouse MGAT1 pro-
moter identiﬁed four putative PPAR-responsive elements
(PPREs) within this region, and luciferase assays showed marked
activation of MGAT1 promoter by PPARγ expression in 293T
cells as well as primary hepatocytes (Fig. 3 C and D). Of these,
−194 and −51 regions strongly bound PPARγ in EMSA
experiments (Fig. 3E and Fig. S6A), demonstrating that MGAT1
is a direct target gene of PPARγ. This result was further con-
ﬁrmed by deletion and mutation analysis of the promoter. As
shown in Fig. S6 A–C, deletion or mutation of −194 and −51
almost completely abolished the promoter activity driven by
PPARγ. It was also conﬁrmed that the mutation of −194 or −51
disrupted the PPARγ binding by EMSA experiment (Fig. S6D).
Finally, a chromatin immunoprecipitation (ChIP) assay was
carried out to conﬁrm the in vivo binding of PPARγ to the
MGAT1 promoter, which was greatly enhanced in HFD-fed and
ob/ob mice (Fig. 3F). Taken together, it is concluded that
PPARγ directly regulates the MGAT1 promoter activity by
binding to both −194 and −51 regions.
MGAT1 Plays an Important Role in the Hepatic Steatosis Induced by
HFD and PPARγ. The liver has the ability to accumulate lipids in
a healthy subject, mainly by the classical glycerol 3-phosphate
pathway. A previous study demonstrated that the MGAT path-
way is merely involved in TG biosynthesis in the normal liver
because of the very low expression and activity of MGAT1 (18).
Our data also show that MGAT1 was not expressed under
a normal diet in B6 and C3H mice (Fig. 3A). To determine the
functional signiﬁcance of the MGAT1 pathway in steatotic liver,
we generated an adenoviral MGAT1-FLAG expression vector,
and the adenovirus was added to AML-12 cells. These cells were
subjected to immunocytochemistry using anti-ADRP antibody,
which localizes to the lipid droplet. As shown in Fig. 4 A–C,
Fig. 2. Adenoviral expression of PPARγ resulted in hepatic steatosis in vivo
in B6 and C3H mice. Mice at 7 wk old were injected with Ad-PPARγ2 or an
Ad-GFP, fed with CD for 1 wk, and then killed. (A) Real-time PCR analysis of
PPARγ2 and its target genes in liver of B6 and C3H mice. (B) Total protein
was isolated from individual livers of Ad-GFP and Ad-PPARγ2 mice. (Upper)
Representative Western blots; (Lower) densitometry results. (C) Hepatic TG
content determined in B6 and C3H mice infected with Ad-GFP or Ad-PPARγ2.
(n = 4.) (D) H&E staining performed on liver sections from mice as shown.
Data in A–C represent the mean ± SD. *P < 0.05, **P < 0.01.
Fig. 3. PPARγ directly regulates MGAT1 promoter activity. (A) MGAT1 mRNA
expression in livers of B6 and C3H mice on a HFD or with Ad-PPARγ2 over-
expression or in primary hepatocytes from B6 and C3H mice with PPARγ
overexpression. (B) PPARγ knockdown in primary hepatocytes isolated from B6
mice resulted in marked reduction of MGAT1 expression, measured by real-
time PCR. (C) The luciferase construct of the 5′-ﬂanking region of the mouse
MGAT1 gene, containing putative PPREs (black squares). (D) Luciferase assay
using mouse MGAT1 promoter. The promoter activity was shown by relative
luciferase activity, with overexpression of RXRα and/or PPARγ2 in either 293T
cells or mouse primary hepatocytes. (E) EMSA experiment of four putative
PPREs on themouseMGAT1 promoter. The oligonucleotides shown in Fig. S6A
were labeled and incubated with TNT-translated mouse PPARγ and RXRα
proteins (*n.s., nonspeciﬁc bands). (F) ChIP assay using anti-PPARγ antibody.
The proximal promoter region ofMGAT1 promoterwas ampliﬁed by real-time
PCR. Data in A, B, D, and F represent the mean ± SD. *P < 0.05*, **P < 0.01.
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MGAT1 overexpression resulted in increased lipid accumulation
in the cells with no increase of other PPARγ-regulated genes.
We also analyzed the effect of MGAT1 overexpression in pri-
mary mouse hepatocyte. To analyze the lipid accumulation by
MGAT1 overexpression in primary hepatocytes, we adopted the
measurement of triglyceride synthesis, using [14C]glycerol (18).
As shown in Fig. 4 D and E, MGAT1 overexpression in primary
hepatocytes resulted in signiﬁcantly increased TG and DAG de
novo synthesis. However, injection of adenovirus expressing
MGAT1-FLAG into mice failed to increase hepatic TG contents
within 1 wk of viral injection (Fig. 4F), suggesting that MGAT1
alone is not sufﬁcient to produce hepatic steatosis in vivo. It is
likely that other PPARγ-regulated genes, such as aP2/422, CD36,
and Fsp27, are required for the enhanced TG synthesis in mice.
To directly demonstrate the role of MGAT1 expression in
PPARγ-induced hepatic steatosis, we generated adenovirus
expressing small hairpin RNA targeting MGAT1 mRNA. We
ﬁrst selected siRNA target sites that efﬁciently suppressed the
MGAT1 expression among siRNAs samples and then produced
two different Ad-shMGAT1 viruses. To test the effect ofMGAT1
knockdown, either adenoviral sh-MGAT1s or a control vector
was injected via tail vein along with an Ad-PPARγ2 virus. As
shown in Fig. 5, the PPARγ-dependent elevation of lipid accu-
mulation was dramatically blunted by knockdown MGAT1, in-
dicating that MGAT1 plays a critical role in the PPARγ-induced
lipid accumulation pathway in liver. Next, we investigated
whether acute reduction of MGAT1 in mice with HFD-induced
hepatic steatosis could affect the amount of TG content in the
liver. Six-week-old B6 mice were fed a HFD for 12 wk and then
injected with adenoviral sh-control or shMGAT1 via tail vein.
After 1 wk with continuous high-fat feeding, mice were killed for
analysis. As shown in Fig. 6 A–C, knockdown of hepatic MGAT1
signiﬁcantly improved hepatic steatosis, without affecting the
expression of PPARγ and its regulatory genes such as aP2/422
and CD36. Hepatic TG content was decreased by 25% after only
1 wk of MGAT1 knockdown (Fig. 6D), suggesting that MGAT1
expression plays a critical role in excessive hepatic lipid accu-
mulation induced by high-fat feeding. Interestingly, hepatic
MGAT1 knockdown also resulted in decreased body weight
along with reduced liver weight, as well as improved glucose
tolerance (Fig. 6 E–G). The biological parameters of these mice
are shown in Fig. 6H, showing that blood glucose but not serum
TG or LDL cholesterol was changed in this short period.
Similarly, the ob/ob mice that develop an obese phenotype
with severe hepatic steatosis were injected with Ad-shMGAT1,
showing dramatic improvement of fatty liver after 1 wk as shown
Fig. 4. MGAT1 overexpression resulted in increased lipid accumulation in
hepatocytes. (A–C) AML-12 cells were infected with adenovirus expressing
MGAT1-FLAG or GFP as a control as indicated. After 2 d, cells were incubated
with palmitate (0.5 mM ﬁnal concentration) in 1% FBS-DMEM for 24 h. (A)
Total cell lysates were analyzed by Western blot analysis with the indicated
antibodies. (B) Total RNA was prepared from the cells and analyzed by real-
time PCR. (C) Double-immunoﬂuorescence staining for FLAG (red) and ADRP
(green) of AML-12 cells. The individual ﬂuorescence values of each antibody
were observed with a confocal microscope. (Scale bar, 50 μm.) (D and E)
Primary mouse hepatocytes were isolated and infected with Ad-MGAT1-
FLAG or GFP, and cells were labeled with [14C]glycerol for 4 h. (D) Western
blot showing MGAT1 overexpression. (E) The [14C]glycerol incorporation
into TG and DAG was counted after TLC of the lipid sample. (F) Adenoviral
expression of MGAT1 in mice was not sufﬁcient to increase hepatic TG
content. Mice were injected with adenovirus, fed with CD for 1 wk, and then
killed. Data in B and E represent the mean ± SD. *P < 0.05, **P < 0.01; n.s.,
not signiﬁcant.
Fig. 5. Knockdown of MGAT1 expression improves hepatic steatosis in
PPARγ-overexpressing liver. B6 mice were injected with either Ad-US (sh-
control) or Ad-sh-MGAT1 along with Ad-GFP or Ad-PPARγ2 via tail vein. Two
different shRNAs targeting MGAT1 cDNA were attempted, designated as sh-
MGAT1-a and sh-MGAT1-b. (A) The liver weights and (B) TG contents were
determined after 1 wk of viral injection. (C) Real-time PCR of the liver
samples showed knockdown of MGAT1 expression. (D) H&E staining was
performed after 1 wk of viral injections with liver sections. Data in A–C
represent the mean ± SD; n = 4. *P < 0.05, **P < 0.01; n.s., not signiﬁcant.
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by H&E staining (Fig. S7). The ob/ob mice treated by shMGAT1
also showed reduced body weight accompanied by signiﬁcantly
decreased epididymal fat content (Fig. S7 A and C). It is not
clear whether the improvement of hepatic steatosis in high-fat–
fed mice and ob/ob mice by MGAT1 knockdown is directly as-
sociated with body weight or systemic insulin resistance; how-
ever, these results suggest that the MGAT1 pathway induced by
hepatic PPARγ is critically important in the development of
hepatic steatosis during diet-induced obesity.
Discussion
In this study, we report evidence for a role of PPARγ-regulated
MGAT1 in hepatic steatosis. One of the critical ﬁndings of this
study was that C3H mice do not express PPARγ and MGAT1 in
the liver and are protected against hepatic steatosis while being
fed a HFD. Importantly, because white adipose tissue of C3H
mice expressed almost the same amount of PPARγ, the observed
resistance to hepatic steatosis is considered liver speciﬁc and not
the result of PPARγ function or expression in other tissues.
Previously, C3H/HeJ mice with a loss-of-function mutation in
the TLR4 gene (14) were reported to be DIO resistant on the
basis of ﬁndings related to adipose tissue (19). However, C3H/
HeN mice carry the wild-type TLR4 and are also reported to be
to resistant to obesity-related disorders similar to their C3H/HeJ
counterparts (20). This controversy might be due to a different
interpretation of the results, because the phenotypes of both
C3H mice are generally different from those of other DIO-prone
mice. As we report in this study, both C3H strains became obese
in response to HFD compared with B6 mice, but neither strain
developed hepatic steatosis to the extent seen in B6 mice, sug-
gesting that TLR4 is not sufﬁcient to explain the accumulation
of excessive lipids in the liver.
The fact that liver-speciﬁc inhibition of PPARγ confers re-
sistance to hepatic steatosis suggests that PPARγ plays pivotal role
in fatty liver, independent of the SREBP1c gene. ApoB/BATless
mice do not show increased levels of hepatic SREBP1c, despite the
presence of insulin resistance and hyperinsulinemia (21). SREBP1c
gene deletion in mice results in a 50% decrease in fatty acid syn-
thesis, indicating that SREBP1c activity alone is not sufﬁcient to
completely eliminate fatty acid synthesis (22). Furthermore,
knockdown of PPARγ2 signiﬁcantly decreased the liver TG con-
tent with a reduction in lipogenic genes in mice fed HFD, with no
alteration of SREBP1c mRNA expression (23). We found that
C3H mice lacking hepatic PPARγ also showed elevated SREBP1c
levels with a HFD, similar to B6 mice, but C3H mice did not de-
velop severe hepatic steatosis, suggesting that PPARγ rather than
SREBP1c directly contributes to fatty liver in response to HFD.
In the present study, adenoviral overexpression of PPARγ2
resulted in marked induction of several PPARγ targets, including
FSP27, aP2/422, CD36, and ADRP. TG accumulation by FSP27
and ADRP may occur through the TG protection from constitu-
tive lipolysis (12, 24, 25). In addition, PPARγ regulates the genes
related to TG synthesis. Of three identiﬁed MGAT enzymes (17,
26, 27), MGAT2 and MGAT3 are highly expressed in the small
intestine, whereas MGAT1 mRNA was detected in stomach,
Fig. 6. Knockdown of MGAT1 improves hepatic steatosis in HFD-induced
hepatic steatosis. (A) Six-week-old B6 mice were fed a HFD for 12 wk and
then injected with adenoviral sh-control or sh-MGAT1 via tail vein. After
1 wk with continuous high-fat feeding, mice were killed. (B) Real-time PCR
analysis showing efﬁcient knockdown of MGAT1 in livers, without changes
of PPARγ and its regulatory genes. (C) H&E staining of liver sections from
mice. (D) Hepatic TG contents were determined. (E) Body weight, liver
weights, and epididymal fat weights were determined. (F) Body weight
changes were measured from the day of viral injection (day 0). (G) After 1 wk
of viral injection, a glucose tolerance test was carried out. (H) Blood pa-
rameter after knockdown of MGAT1. Data in B and D–H represent the mean ±
SD; n = 6/6. *P < 0.05, **P < 0.01.
Fig. 7. A proposed model for the role of PPARγ and its regulation of target
genes in hepatic steatosis. In diet-induced hepatic steatosis, increased ac-
tivity of PPARγ and resulting increased MGAT1 expression enhance TG ac-
cumulation, regardless of fatty acid synthesis regulated by SREBP1c. ACS,
acyl Co-A synthetase; DAG, diacylglycerol; G3P, glycerol-3-phosphate; GPAT,
glycerol-3-phosphate acyltransferases; LPA, lysophosphatidic acid; LPP, lipid
phosphate phosphatase, MAG, monoacylglycerol; PA, phosphatidic acid.
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adipose tissue, and kidney. We showed that MGAT1 expression
was very low in normal liver but was highly expressed in the fatty
liver. We also demonstrate that the MGAT1 gene is directly
regulated by PPARγ. This result is important because PPARγmay
contribute to rapid TG incorporation via alternative pathways
using increased MGAT1 enzyme. Indeed, we show that expres-
sion of adenoviral PPARγ in primary hepatocytes or mouse livers
induced MGAT1 expression. Moreover, we observed the sup-
pression of MGAT1 expression protected liver from fatty changes
in three models: Ad-PPARγ-induced steatosis, 12-wk HFD-in-
duced steatosis, and ob/ob mice with hepatic steatosis. It is likely
that several PPARγ-regulated genes, such as aP2/422, CD36, and
MGAT1, coordinate the enhanced TG accumulation in HFD-
induced severe steatosis. However, blocking the MGAT1-associ-
ated alternative pathway might be an effective way to reduce the
severity of PPARγ-induced hepatic steatosis in diet-induced
obesity. It remains to be clariﬁed by further study whether the
inhibition of hepatic MGAT1 affects the body weight change or
glucose tolerance.
On the basis of these data, we propose a model for the role of
PPARγ in hepatic steatosis (Fig. 7). When plasma fatty acids are
elevated either by diet or by release from adipose tissue, hepatic
PPARγ is up-regulated and consequently activates fatty acid
transporters and binding proteins, including CD36 and aP2/422. As
a result, fatty acid uptake is markedly increased in hepatocytes.
Fatty acids are then converted to fatty acyl CoA, which is ultimately
esteriﬁed to TG. In addition, up-regulation of PPARγ in hep-
atocytes dramatically activates the MGAT pathway. Mono-
acylglycerol could also be generated from chylomicron remnants or
hepatic TG, eventually increasing TG accumulation in the hep-
atocytes. In conclusion, PPARγ is responsible for activating the
expression of genes involved in fatty acid uptake and TG synthesis,
and the inhibition of PPARγ-induced MGAT1 for the alternative
TG synthesis pathway would be one of the excellent therapeutic
targets for hepatic steatosis.
Materials and Methods
Mice and Diet.Male C57BL/6J, C3H/HeN, or C3H/HeJmice were purchased from
SLC. The animals were maintained in a temperature-controlled room (22 °C)
on a 12:12-h light–dark cycle. Five- or 6-wk-old mice were fed a HFD (Research
Diets) or a normal diet (Dyets) for up to 12 wk. The composition of the HFD
we used was 60 kcal% fat containing 0 g/kg of corn starch, 125 g/kg of
maltodextrin 10, 68.8 g/kg of sucrose, and 245 g/kg of lard. Body weight was
measured once a week. All procedures were approved by the Committee on
Animal Investigations of Yonsei University.
Preparation of Recombinant Adenovirus. Murine PPARγ2 and MGAT1 cDNAs
were cloned into pcDNA3 vector or FLAG-tagged pcDNA3, respectively.
Recombinant adenovirus expressing PPARγ2 and MGAT1-FLAG and ad-
shRNA for MGAT1 were prepared. Recombinant adenovirus containing the
GFP gene or Ad-US control RNAi was used as a control.
Fatty Acid Uptake Assay. Fatty acid uptake was measured with the QBT Fatty
Acid Uptake Assay kit (Molecular Probes) according to the manufacturer’s
instructions. QBT Fatty Acid Uptake Assay stock solutions were dissolved
completely by adding 10 mL of 1× HBSS buffer.
In Vivo Effect of Adenovirus. Seven-week-old male C57BL/6 mice and C3H/HeJ
mice were injected with Ad-PPARγ2, Ad-MGAT1, or control recombinant
adenovirus. Recombinant adenovirus (2 × 109 pfu) was delivered by tail-vein
injection to mice. Seven days after injection, mice were killed by terminal
anesthesia. Similarly, ob/ob mice were used for the adenoviral injection via
tail veins as described.
Immunoﬂuorescence. Cells were cultured in 12 wells on glass coverslips and
ﬁxed in MeOH/acetone (1:1) at −20 °C for 30 min and blocked with 3% (wt/
vol) BSA in PBS for 1 h. Cells were incubated for 2 h at room temperature
(RT) with primary antibodies. Cells were washed and incubated with
Alexa488- or Alexa555-conjugated secondary antibodies (Invitrogen) for 1 h
at RT. Nuclei were revealed with DAPI staining. Confocal scanning was
performed on an LSM700 scanning microscope (Carl Zeiss).
Statistical Analysis. All results are expressed as mean ± SEM. Statistical
comparisons of groups were made using an unpaired Student’s t test and
two-way ANOVA.
For full details of all methods, please refer to SI Materials and Methods.
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